CCL2 produced by CD68+/CD163+ macrophages as a promising clinical biomarker of microscopic polyangiitis-interstitial lung disease.

Shogo MatsudaTakuya KotaniHiroko KuwabaraTakayasu SuzukaTakao KiboshiKeisuke FukuiTakaaki IshidaYouhei FujikiHideyuki ShibaKenichiro HataTakeshi ShodaYoshinobu HiroseTohru Takeuchi

Published in: Rheumatology (Oxford, England) (2021)

CCL2 is associated with MPA-ILD pathogenesis and suggested its potential efficacy as a useful marker for diagnosing and predicting MPA-ILD progression. Therefore, targeting CCL2 in alveolar CD68+/CD163+ macrophages might represent a therapeutic intervention in ANCA+ MPA-ILD.

Keyphrases

interstitial lung disease
systemic sclerosis
liver fibrosis
rheumatoid arthritis
liver injury
idiopathic pulmonary fibrosis
randomized controlled trial
drug induced